Regeneron
Executive Director, CMC Program Management (Chemistry)
Regeneron, Troy, New York, United States
We are hiring an Executive Director to lead program management for a portfolio of chemistry‑based advanced therapies (ADC, siRNA, mRNA, oligonucleotides, conjugates, peptides). Responsible for end‑to‑end operational coordination—linking Manufacturing, R&D, CMC, clinical, regulatory—to enable accelerated development and commercialization of advanced therapy treatments.
In this role, a typical day might include the following:
Lead and develop a team of 6–10 program managers overseeing 20–30 active programs across clinical and commercial stages.
Drive timeline acceleration and optimization, balancing priorities across internal and external manufacturing capacity, regulatory milestones, and resource constraints.
Work closely with clinical, development and manufacturing teams to proactively identify and resolve development and supply bottlenecks impacting clinical, regulatory or commercial deliverables.
Oversee clinical and commercial launch supply readiness through coordination with internal teams and external manufacturing group.
Support data flow and documentation to enable submissions by CMC regulatory teams, ensuring timely and complete packages.
Collaborate with Finance to inform investment needs and help secure program budgets in a timely manner.
Provide program management leadership for tech transfers, manufacturing readiness, and process scale‑up.
Coordinate post‑launch activities including lifecycle expansions, process improvements, and indication growth.
Establish governance tools, dashboards, and metrics for portfolio visibility and decision‑making.
Qualifications
Demonstrated success managing cross‑functional timelines under complex capacity, regulatory, and technical constraints.
Strong understanding of process chemistry, analytical development, conjugation technologies, and tech transfer.
Proven ability to partner with scientists and engineers to drive efficient execution and innovation.
To be considered for this role you must hold a Bachelors degree, with 18+ years of experience in Biopharma Operations, CMC, or Program Management with direct experience in ADC, siRNA, or mRNA product development and successful launches, or equivalent combination of education and experience.
Ph.D. or M.S. in Chemistry, Biochemistry, Chemical Engineering, or Pharmaceutical Sciences preferred.
Salary Range (annually)
$239,600.00 - $399,400.00
Regeneron is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion or belief (or lack thereof), sex, nationality, national or ethnic origin, civil status, age, citizenship status, membership of the Traveler community, sexual orientation, disability, genetic information, familial status, marital or registered civil partnership status, pregnancy or parental status, gender identity, gender reassignment, military or veteran status, or any other protected characteristic in accordance with applicable laws and regulations. The Company will also provide reasonable accommodation to the known disabilities or chronic illnesses of an otherwise qualified applicant for employment, unless the accommodation would impose undue hardship on the operation of the Company’s business.
#J-18808-Ljbffr
In this role, a typical day might include the following:
Lead and develop a team of 6–10 program managers overseeing 20–30 active programs across clinical and commercial stages.
Drive timeline acceleration and optimization, balancing priorities across internal and external manufacturing capacity, regulatory milestones, and resource constraints.
Work closely with clinical, development and manufacturing teams to proactively identify and resolve development and supply bottlenecks impacting clinical, regulatory or commercial deliverables.
Oversee clinical and commercial launch supply readiness through coordination with internal teams and external manufacturing group.
Support data flow and documentation to enable submissions by CMC regulatory teams, ensuring timely and complete packages.
Collaborate with Finance to inform investment needs and help secure program budgets in a timely manner.
Provide program management leadership for tech transfers, manufacturing readiness, and process scale‑up.
Coordinate post‑launch activities including lifecycle expansions, process improvements, and indication growth.
Establish governance tools, dashboards, and metrics for portfolio visibility and decision‑making.
Qualifications
Demonstrated success managing cross‑functional timelines under complex capacity, regulatory, and technical constraints.
Strong understanding of process chemistry, analytical development, conjugation technologies, and tech transfer.
Proven ability to partner with scientists and engineers to drive efficient execution and innovation.
To be considered for this role you must hold a Bachelors degree, with 18+ years of experience in Biopharma Operations, CMC, or Program Management with direct experience in ADC, siRNA, or mRNA product development and successful launches, or equivalent combination of education and experience.
Ph.D. or M.S. in Chemistry, Biochemistry, Chemical Engineering, or Pharmaceutical Sciences preferred.
Salary Range (annually)
$239,600.00 - $399,400.00
Regeneron is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion or belief (or lack thereof), sex, nationality, national or ethnic origin, civil status, age, citizenship status, membership of the Traveler community, sexual orientation, disability, genetic information, familial status, marital or registered civil partnership status, pregnancy or parental status, gender identity, gender reassignment, military or veteran status, or any other protected characteristic in accordance with applicable laws and regulations. The Company will also provide reasonable accommodation to the known disabilities or chronic illnesses of an otherwise qualified applicant for employment, unless the accommodation would impose undue hardship on the operation of the Company’s business.
#J-18808-Ljbffr